Your session is about to expire
← Back to Search
Oncolytic Virus + CAR T-Cell Therapy for Solid Cancers (VISTA Trial)
VISTA Trial Summary
This trial is testing the safety and effectiveness of two cancer treatments: CAdVEC, an oncolytic adenovirus that is designed to help the immune system, and HER2-specific CAR T cells.
VISTA Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowVISTA Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.VISTA Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I can take care of myself but cannot do heavy physical work.I have a tumor that can be injected directly.I had HER2 targeted therapy over 4 weeks ago.I have been diagnosed with HIV or another immune system disorder.I haven't had any cancer except for some skin, thyroid, prostate, or cervical cancers in the last 5 years.My cancer is considered untreatable with surgery, radiation, or medications by my oncologist.My organs are functioning well enough for treatment.I am on continuous medication for an autoimmune disease.My solid tumor is HER2 positive based on a test.My liver tests are within the required limits.I have had an organ transplant.I am not on any treatments that could interfere with the study, except possibly low-dose steroids or stable brain treatments.My tumor is in a location that could cause serious bleeding if injected.My cancer is HER2 positive and includes types like breast or lung cancer.You have a medical condition that weakens your immune system and makes it harder for your body to fight infections.There is a chance that the treatment may cause swelling in certain areas of your body that could block important passages, like your airway or digestive system.I do not have an active infection like hepatitis B or C.I had a heart attack within the last 6 months.My kidney function is within the normal range.My condition worsened after initial treatment or there are no effective treatments available.My heart's left ventricle is not pumping well.I am not pregnant and will use birth control during the study, or I cannot get pregnant.I am 18 or older and can understand and agree to the study's procedures.I agree to use barrier contraception to prevent pregnancy during the study.
- Group 1: Treatment Phase
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is there still availability for individuals to join this research project?
"Based on the clinicaltrials.gov registry, this study is actively searching for eligible individuals to participate. The trial was initially posted on December 14th 2020 with its most recent update having been done August 24th 2022."
Is CAdVEC a viable option for patients with regards to safety and efficacy?
"Our team at Power assigned a score of 1 to CAdVEC's safety due to its current status as a Phase 1 trial, implying that there is limited information on the drug's efficacy and risk profile."
What is the aggregate patient count involved in this clinical research?
"Correct. The information on clinicaltrials.gov affirms that this trial, which was initially published on December 14th 2020, is presently accepting participants. 45 individuals need to be found from 1 medical centre."
Share this study with friends
Copy Link
Messenger